肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

2021 SGO临床实践声明：复发性卵巢癌二次减瘤手术

2021-10-19 美国妇科肿瘤学会 Gynecol Oncol

复发性卵巢癌

减瘤手术和全身化疗是晚期疾病患者一线治疗的基础。关于二次减瘤手术（SCR）能否提高复发性卵巢癌患者的总体生存率的现有前瞻性证据好坏各半。

中文标题：

2021 SGO临床实践声明：复发性卵巢癌二次减瘤手术

英文标题：

Secondary cytoreductive surgery for recurrent ovarian cancer: An SGO clinical practice statement

发布机构：

美国妇科肿瘤学会

发布日期：

2021-10-19

简要介绍：

减瘤手术和全身化疗是晚期疾病患者一线治疗的基础。关于二次减瘤手术（SCR）能否提高复发性卵巢癌患者的总体生存率的现有前瞻性证据好坏各半。本文概述了复发卵巢癌患者SCR的基本原理、背景和当代临床试验，并促进这些患者的知情决策和治疗计划。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 SGO临床实践声明：复发性卵巢癌二次减瘤手术.pdf)] GetToolGuiderByIdResponse(projectId=1, id=2de161c0022392ca, title=2021 SGO临床实践声明：复发性卵巢癌二次减瘤手术, enTitle=Secondary cytoreductive surgery for recurrent ovarian cancer: An SGO clinical practice statement, guiderFrom=Gynecol Oncol, authorId=0, author=, summary=减瘤手术和全身化疗是晚期疾病患者一线治疗的基础。关于二次减瘤手术（SCR）能否提高复发性卵巢癌患者的总体生存率的现有前瞻性证据好坏各半。, cover=https://img.medsci.cn/20211026/1635260375304_1608702.jpg, journalId=0, articlesId=null, associationId=1177, associationName=美国妇科肿瘤学会, associationIntro=The Society of Gynecologic Oncology (SGO) is the premier medical specialty society for health care professionals trained in the comprehensive management of gynecologic cancers. As a 501(c)(6) organization, the SGO contributes to the advancement of women&rsquo;s cancer care by encouraging research, providing education, raising standards of practice, advocating for patients and members and collaborating with other domestic and international organizations., copyright=0, guiderPublishedTime=Tue Oct 19 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">减瘤手术和全身化疗是晚期疾病患者一线治疗的基础。关于二次减瘤手术（SCR）能否提高复发性卵巢癌患者的总体生存率的现有前瞻性证据好坏各半。本文概述了复发卵巢癌患者SCR的基本原理、背景和当代临床试验，并促进这些患者的知情决策和治疗计划。</span></p>, tagList=[TagDto(tagId=49570, tagName=复发性卵巢癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=28, categoryName=整形科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21052, categoryName=梅斯医学-卵巢癌网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=49570, guiderKeyword=复发性卵巢癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=1, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=8752, appHits=54, showAppHits=0, pcHits=424, showPcHits=8698, likes=0, shares=4, comments=1, approvalStatus=1, publishedTime=Tue Oct 26 23:11:12 CST 2021, publishedTimeString=2021-10-19, pcVisible=1, appVisible=1, editorId=1608702, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=dajiong, createdTime=Tue Oct 26 23:03:43 CST 2021, updatedBy=1608702, updatedName=dajiong, updatedTime=Sat Jan 06 20:35:23 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 SGO临床实践声明：复发性卵巢癌二次减瘤手术.pdf)])
2021 SGO临床实践声明：复发性卵巢癌二次减瘤手术.pdf
下载请点击：
评论区 (1)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1064261, encodeId=69d51064261a6, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Wed Oct 27 07:02:23 CST 2021, time=2021-10-27, status=1, ipAttribution=)]
    2021-10-27 微探

    学习学习

    0

相关指南

PARP抑制剂治疗复发性卵巢癌专家共识

妇产科相关专家组（统称） · 2018-10-20

拓展阅读

PARP抑制剂治疗复发性卵巢癌专家共识

妇产科相关专家组（统称） · 2018-10-20